atezolizumab (tecentriq) Report issue

Biologics mAb Approved FDA First in Class Accelerated Approval FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Atezolizumab, sold under the brand name Tecentriq, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), and hepatocellular carcinoma (HCC). It is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$3854.5900 - $5506.5605

United States

$4740.2800 - $9047.4400
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

anti-pdl1 | anti-pd-l1 | atelolizumab | atezolizumab | immunoglobulin g1, anti-(human cd antigen cd274) (human monoclonal mdpl3280a heavy chain), disulfide with human monoclonal mdpl3280a kappa-chain, dimer | mpdl3280a | mpdl-3280a | rg7446 | rg-7446 | tecentriq

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue